Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03408574 · ClinicalTrials.gov registry record · Phase 1
The Nicotinic Cholinergic System and Cognitive Aging
A Phase 1 study of Healthy Aging, sponsored by University of Vermont.
- Completed
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
- 1
- Study location
NCT03408574 is a Phase 1 study of Healthy Aging that has completed, run by University of Vermont. The registered enrollment target is 104 participants, below the 119-participant average among 40 other Healthy Aging trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03408574, a Phase 1 study of Healthy Aging, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
Prior research has shown that a chemical system in the brain called the cholinergic system is primarily responsible for cognitive symptoms seen in people with dementia. While therapeutic benefits are clear in dementia, what remains uncertain is the role that the cholinergic system in general and a subset of receptors called the nicotinic system plays in cognition in healthy non-demented older adults (referred to as normal cognitive aging). This is critical because the ever growing healthy aging population will show declines in cognition that fall short of dementia but still impact functional abilities and independence. Maintaining good nicotinic system functioning throughout adulthood may lessen the cognitive symptoms of aging. At this time, it is not clear what the biological cause of age-related changes in cognition is. This study will examine the role of the nicotinic system in the healthy aging brain and examine its role in memory and thinking processes in older and younger adults.
Conditions Studied
Interventions
- DRUG Nicotine patch, oral mecamylamine, placebo
Study Locations (1)
Vermont
- University of Vermont - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2016-10-01 |
| Est. Completion | 2022-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03408574
The ClinicalTrials.gov registry entry for NCT03408574 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 40 other Healthy Aging trials with a reported enrollment target (13% lower). The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Aging appearing as the primary indexed condition, and to 1 intervention - of which Nicotine patch, oral mecamylamine, placebo is the first listed.
NCT03408574 reports 1 study location spanning 1 distinct geographic area - top geographies include Vermont.
Frequently Asked Questions
What is clinical trial NCT03408574 about?
NCT03408574 is a clinical study titled "The Nicotinic Cholinergic System and Cognitive Aging". Prior research has shown that a chemical system in the brain called the cholinergic system is primarily responsible for cognitive symptoms seen in people with dementia. While therapeutic benefits are clear in dementia, what remains uncertain is the role that the cholinergic system in general and a s...
What is the current status of trial NCT03408574?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2016-10-01. Estimated completion is 2022-01-31.
What conditions does trial NCT03408574 study?
This clinical trial studies the following conditions: Healthy Aging.
What interventions are being tested in trial NCT03408574?
The interventions under investigation include: Nicotine patch, oral mecamylamine, placebo (DRUG).
Who is sponsoring clinical trial NCT03408574?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03408574 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Executive Control in Cognitively Healthy Older Adults: the MUltitasking STrategy (MUST) Study
RECRUITING · NA
-
The Mitopure Challenge to Detect Levels of Urolithin A in Dried Blood Spots
RECRUITING · NA
-
Exercise to Improve Brain Health in Older African Americans
RECRUITING · Phase 2
-
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
RECRUITING · NA
-
Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging
RECRUITING · NA
-
iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.